Which has better valuation & earnings, IXI or REDX?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.27 -£3.58M -£1.95 N/A Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A

Is IXI or REDX more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% Redx Pharma N/A -180.80% -43.95%

Is POLB or IXI more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -71.28% -21.33% IXICO -24.98% -16.18% -10.40%

Does the media prefer POLB or IXI?

In the previous week, Poolbeg Pharma had 1 more articles in the media than IXICO. MarketBeat recorded 2 mentions for Poolbeg Pharma and 1 mentions for IXICO. IXICO's average media sentiment score of 0.67 beat Poolbeg Pharma's score of 0.53 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IXICO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IXI or ETX?

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.27 -£3.58M -£1.95 N/A e-therapeutics £295K 0.00 -£10.06M -£0.02 N/A

Is IXI or ETX more profitable?

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% e-therapeutics N/A -38.75% -29.10%

Do analysts recommend IXI or HVO?

hVIVO has a consensus price target of GBX 16.33, suggesting a potential upside of 181.12%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher earnings & valuation, IXI or HVO?

hVIVO has higher revenue and earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.27 -£3.58M -£1.95 N/A hVIVO £38.85M 1.03 £17.84M -£1.78 N/A

Is IXI or HVO more profitable?

IXICO has a net margin of -24.98% compared to hVIVO's net margin of -31.76%. IXICO's return on equity of -16.18% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% hVIVO -31.76% -35.13% 11.97%

Does the media refer more to IXI or HVO?

In the previous week, hVIVO had 5 more articles in the media than IXICO. MarketBeat recorded 6 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.67 beat hVIVO's score of 0.47 indicating that IXICO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IXICO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive hVIVO 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IXICO (IXI) Competitors

GBX 7.55 -0.20 (-2.58%)

As of 11:41 AM Eastern

Compare

IXI vs. REDX, POLB, ETX, HEMO, and HVO

Should you buy IXICO stock or one of its competitors? IXICO's main competitors and comparable companies include Redx Pharma (REDX), Poolbeg Pharma (POLB), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), and hVIVO (HVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IXICO compare to Redx Pharma?

IXICO (LON:IXI) and Redx Pharma (LON:REDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.27	-£3.58M	-£1.95	N/A
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A

IXICO has a beta of 0.106, meaning that its share price is 89% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market.

30.6% of IXICO shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 3.1% of IXICO shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, IXICO had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 0.67 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
Redx Pharma	Neutral

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Redx Pharma	N/A	-180.80%	-43.95%

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 30.6% of IXICO shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 3.1% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Poolbeg Pharma had 1 more articles in the media than IXICO. MarketBeat recorded 2 mentions for Poolbeg Pharma and 1 mentions for IXICO. IXICO's average media sentiment score of 0.67 beat Poolbeg Pharma's score of 0.53 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IXICO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Poolbeg Pharma has a beta of 1.828, indicating that its share price is 83% more volatile than the broader market. Comparatively, IXICO has a beta of 0.106, indicating that its share price is 89% less volatile than the broader market.

IXICO has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.79	N/A
IXICO	£7.28M	2.27	-£3.58M	-£1.95	N/A

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-71.28%	-21.33%
IXICO	-24.98%	-16.18%	-10.40%

Summary

IXICO beats Poolbeg Pharma on 7 of the 12 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

IXICO (LON:IXI) and e-therapeutics (LON:ETX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
e-therapeutics	N/A	-38.75%	-29.10%

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.27	-£3.58M	-£1.95	N/A
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A

In the previous week, IXICO had 1 more articles in the media than e-therapeutics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for e-therapeutics. IXICO's average media sentiment score of 0.67 beat e-therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
e-therapeutics	Neutral

30.6% of IXICO shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 3.1% of IXICO shares are owned by company insiders. Comparatively, 59.4% of e-therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Summary

IXICO beats e-therapeutics on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than IXICO. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£130.80	N/A
IXICO	£7.28M	2.27	-£3.58M	-£1.95	N/A

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%
IXICO	-24.98%	-16.18%	-10.40%

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 30.6% of IXICO shares are held by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, IXICO had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Hemogenyx Pharmaceuticals. IXICO's average media sentiment score of 0.67 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
IXICO	Positive

Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its stock price is 49% more volatile than the broader market. Comparatively, IXICO has a beta of 0.106, indicating that its stock price is 89% less volatile than the broader market.

Summary

IXICO beats Hemogenyx Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does IXICO compare to hVIVO?

IXICO (LON:IXI) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

hVIVO has higher revenue and earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.27	-£3.58M	-£1.95	N/A
hVIVO	£38.85M	1.03	£17.84M	-£1.78	N/A

hVIVO has a consensus price target of GBX 16.33, suggesting a potential upside of 181.12%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

IXICO has a net margin of -24.98% compared to hVIVO's net margin of -31.76%. IXICO's return on equity of -16.18% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
hVIVO	-31.76%	-35.13%	11.97%

30.6% of IXICO shares are owned by institutional investors. Comparatively, 12.7% of hVIVO shares are owned by institutional investors. 3.1% of IXICO shares are owned by company insiders. Comparatively, 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, hVIVO had 5 more articles in the media than IXICO. MarketBeat recorded 6 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.67 beat hVIVO's score of 0.47 indicating that IXICO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IXICO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
hVIVO	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IXICO has a beta of 0.106, suggesting that its share price is 89% less volatile than the broader market. Comparatively, hVIVO has a beta of 1.694, suggesting that its share price is 69% more volatile than the broader market.

Summary

hVIVO beats IXICO on 11 of the 16 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.53M	£3.89B	£7.28B	£2.81B
Dividend Yield	1.27%	3.65%	2.51%	6.26%
P/E Ratio	-3.87	12.99	275.44	366.75
Price / Sales	2.27	1,141.69	559.80	88,865.19
Price / Cash	2.25	118.50	77.16	27.85
Price / Book	0.39	16.88	10.66	7.12
Net Income	-£3.58M	-£22.65M	£3.50B	£5.89B
7 Day Performance	-5.63%	-5.64%	-3.65%	0.21%
1 Month Performance	5.59%	-13.53%	-8.06%	-0.04%
1 Year Performance	-34.97%	6.87%	2.58%	22.93%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 7.55 -2.6%	N/A	-37.1%	£16.53M	£7.28M	N/A	79	Gap Up
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
POLB Poolbeg Pharma	N/A	GBX 7.20 +2.9%	N/A	+80.5%	£54.97M	N/A	N/A	12
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 690 -1.4%	N/A	-31.8%	£46.92M	N/A	N/A	14	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors

IXI vs. REDX, POLB, ETX, HEMO, and HVO

How does IXICO compare to Redx Pharma?

Summary

How does IXICO compare to Poolbeg Pharma?

Summary

How does IXICO compare to e-therapeutics?

Summary

How does IXICO compare to Hemogenyx Pharmaceuticals?

Summary

How does IXICO compare to hVIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXI vs. The Competition

IXICO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IXICO (IXI) Competitors

IXI vs. REDX, POLB, ETX, HEMO, and HVO

How does IXICO compare to Redx Pharma?

Which has better valuation & earnings, IXI or REDX?

Which has more risk & volatility, IXI or REDX?

Do institutionals and insiders have more ownership in IXI or REDX?

Does the media favor IXI or REDX?

Is IXI or REDX more profitable?

Summary

How does IXICO compare to Poolbeg Pharma?

Do institutionals and insiders hold more shares of POLB or IXI?

Does the media prefer POLB or IXI?

Which has more volatility and risk, POLB or IXI?

Which has stronger valuation and earnings, POLB or IXI?

Is POLB or IXI more profitable?

Summary

How does IXICO compare to e-therapeutics?

Is IXI or ETX more profitable?

Which has stronger earnings and valuation, IXI or ETX?

Does the media refer more to IXI or ETX?

Do institutionals and insiders have more ownership in IXI or ETX?

Which has more volatility and risk, IXI or ETX?

Summary

How does IXICO compare to Hemogenyx Pharmaceuticals?

Which has stronger earnings & valuation, HEMO or IXI?

Is HEMO or IXI more profitable?

Do insiders & institutionals believe in HEMO or IXI?

Does the media prefer HEMO or IXI?

Which has more volatility and risk, HEMO or IXI?

Summary

How does IXICO compare to hVIVO?

Which has higher earnings & valuation, IXI or HVO?

Do analysts recommend IXI or HVO?

Is IXI or HVO more profitable?

Do insiders and institutionals hold more shares of IXI or HVO?

Does the media refer more to IXI or HVO?

Which has more risk and volatility, IXI or HVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXI vs. The Competition

IXICO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools